Ovid Therapeutics Inc.(OVID)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• Ovid Therapeutics faces a precarious financial outlook characterized by a total reliance on unpredictable milestone payments, as evidenced by the 100% year-over-year revenue decline in 2026Q1.
• The company's inability to generate recurring commercial income, coupled with a rigid R&D cost structure averaging $8.5 million per quarter, suggests a high probability of continued equity dilution.
• Investors should monitor the company's ability to extend its operational runway, given that cash reserves have compressed significantly from $94.1 million in 2026Q1 to $13.2 million by 2025Q4.